Background
==========

*P. vivax* is the most geographically widespread human malaria and is considered to be the most prevalent form in some regions of Latin America, Central and South-East Asia, accounting for up to 390 million clinical infections every year and an estimated 2.6 billion people being at risk of infection with *P. vivax*\[[@B1],[@B2]\]. An effective vaccine against this protozoan would have a major global impact on the disease burden \[[@B3]\]. Modified Vaccinia Ankara (MVA) and the chimpanzee adenovirus ChAd63 are two clinically relevant viral vectors that have been shown to induce strong and protective antibody and T-cell responses against *P. falciparum* TRAP, both in pre-clinical studies and clinical trials \[[@B4]-[@B7]\].

Materials and methods
=====================

We developed recombinant ChAd63 and MVA vectors expressing *P. vivax* TRAP (PvTRAP), which were used to assess T-cell and antibody responses upon sequential immunisation (prime-boost) of mice. Vaccine efficacy was assessed through challenge with a newly developed transgenic *P. berghei* expressing PvTRAP.

Results
=======

High antibody titres and frequencies of PvTRAP-specific T cells were induced in all tested inbred and outbred mouse strains. The newly developed parasite showed similar fitness to wild type *P. berghei* and was successfully used to infect and assess protection in vaccinated mice. The Ad-MVA prime-boost regimen induced good protective levels regardless of the mouse strain.

Conclusions
===========

The strong immunogenicity and protective efficacy elicited by the recombinant ChAd63 and MVA viruses expressing PvTRAP indicate that this vaccine approach has a good potential to be tested in clinical trials in the near future.
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